Skip to main content
PROKIDNEY CORP. logo

PROKIDNEY CORP. — Investor Relations & Filings

Ticker · PROK ISIN · KYG8253W1096 US Manufacturing
Filings indexed 371 across all filing types
Latest filing 2021-09-24 Director's Dealing
Country US United States of America
Listing US PROK

About PROKIDNEY CORP.

https://prokidney.com/

ProKidney Corp. is a late clinical-stage biotechnology company developing a proprietary, first-in-class cell therapy platform for the treatment of advanced Chronic Kidney Disease (CKD). Its lead investigational candidate, rilparencel, is an autologous therapy derived from a patient's own kidney cells, which are obtained via a standard biopsy. The therapeutic approach aims to preserve remaining kidney function. Rilparencel is being evaluated for its potential to slow disease progression, with the goal of delaying or eliminating the need for dialysis in patients with limited treatment options.

Recent filings

Filing Released Lang Actions
FORM 3 SUBMISSION
Director's Dealing
2021-09-24 English
8-K
Regulatory Filings
2021-09-24 English
FORM 4 SUBMISSION
Director's Dealing
2021-08-17 English
FORM 10-Q
Interim / Quarterly Report Q2 2021
2021-08-16 English
SOCIAL CAPITAL SUVRETTA HOLDINGS CORP. III
Major Shareholding Notification
2021-07-12 English
FORM 8-K
Regulatory Filings
2021-07-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.